| A Web-Based and Mobile Intervention Program Using a Spaced Education Approach for Workplace Mental Health Literacy: Cluster Randomized Controlled Trial.JMIR Ment Health | PMID 38654570PMC11063580 | 2024-Apr-23 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Vonoprazan 10 mg or 20 mg vs. lansoprazole 15 mg as maintenance therapy in Asian patients with healed erosive esophagitis: A randomized controlled trial.Chin Med J (Engl) | PMID 38654422PMC11046018 | 2024-Apr-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Gene Expression Signatures Predict First-Year Response to Somapacitan Treatment in Children With Growth Hormone Deficiency.J Clin Endocrinol Metab | PMID 38066644PMC11031233 | 2024-Apr-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Equivalence trial of proposed denosumab biosimilar GP2411 and reference denosumab in postmenopausal osteoporosis: the ROSALIA study.J Bone Miner Res | PMID 38477751PMC11338045 | 2024-Apr-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.N Engl J Med | PMID 38631003无 PMCID | 2024-Apr-18 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials.Br J Dermatol | PMID 38226713无 PMCID | 2024-Apr-17 | 0.95 | The report is for plaque psoriasis, a non-oncology condition. Although it meets other criteria (human, randomized, Phase III, drug intervention, original result), it is not an oncology study and lacks a time-to-event efficacy endpoint. | 待处理 |
| Malnutrition enteropathy in Zambian and Zimbabwean children with severe acute malnutrition: A multi-arm randomized phase II trial.Nat Commun | PMID 38632262PMC11024201 | 2024-Apr-17 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial.J Headache Pain | PMID 38627638PMC11020209 | 2024-Apr-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Assessing Per-Sex-Act HIV-1 Risk Reduction Among Women Using the Dapivirine Vaginal Ring.J Infect Dis | PMID 38099506PMC11011174 | 2024-Apr-12 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study.RMD Open | PMID 38609322PMC11029242 | 2024-Apr-12 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.N Engl J Med | PMID 38598794无 PMCID | 2024-Apr-11 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Clinical and nutritional correlates of bacterial diarrhoea aetiology in young children: a secondary cross-sectional analysis of the ABCD trial.BMJ Paediatr Open | PMID 38604769PMC11015214 | 2024-Apr-11 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Oral arsenic plus imatinib versus imatinib solely for newly diagnosed chronic myeloid leukemia: a randomized phase 3 trial with 5-year outcomes.J Cancer Res Clin Oncol | PMID 38605258PMC11009770 | 2024-Apr-11 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04).J Clin Oncol | PMID 37861993PMC11095857 | 2024-Apr-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.J Clin Oncol | PMID 38227898PMC11095851 | 2024-Apr-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722.J Clin Oncol | PMID 38252907PMC11095864 | 2024-Apr-10 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.J Clin Oncol | PMID 38301187PMC11095886 | 2024-Apr-10 | 0.95 | The report is a Phase III randomized trial of a drug (olaparib) in human breast cancer, but the primary and secondary endpoints are patient-reported outcomes (PROs) like fatigue, nausea, and vomiting, measured at fixed time points. It does not report a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, or any Kaplan-Meier analysis or hazard ratio for time-to-event). | 待处理 |
| Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2.RMD Open | PMID 38599650PMC11015249 | 2024-Apr-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Influence of vitamin D supplementation on growth, body composition, pubertal development and spirometry in South African schoolchildren: a randomised controlled trial (ViDiKids).BMJ Paediatr Open | PMID 38599800PMC11015302 | 2024-Apr-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study.BMC Cancer | PMID 38589856PMC11003088 | 2024-Apr-08 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| SABR-Dual: a phase II/III trial of two-fraction versus five-fraction stereotactic radiotherapy for localized low- and favorable intermediate-risk prostate cancer.BMC Cancer | PMID 38589860PMC11000374 | 2024-Apr-08 | 0.85 | This is a protocol for a phase II/III randomized controlled trial in prostate cancer with a time-to-event primary endpoint. However, it is a radiation therapy study with no drug intervention (SABR vs. SABR). Furthermore, it is a protocol without results, not an original result report. | 待处理 |
| Perioperative versus adjuvant S-1 plus oxaliplatin chemotherapy for stage II/III resectable gastric cancer (RESONANCE): a randomized, open-label, phase 3 trial.J Hematol Oncol | PMID 38589926PMC11003079 | 2024-Apr-08 | 0.99 | 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 | 待处理 |
| Optimised prevention of postnatal HIV transmission in Zambia and Burkina Faso (PROMISE-EPI): a phase 3, open-label, randomised controlled trial.Lancet | PMID 38484756无 PMCID | 2024-Apr-06 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Patient, family caregiver, and economic outcomes of an integrated screening and novel stepped collaborative care intervention in the oncology setting in the USA (CARES): a randomised, parallel, phase 3 trial.Lancet | PMID 38490230PMC11556417 | 2024-Apr-06 | 0.90 | The trial is eligible for inclusion based on oncology, human, randomized, phase 3, original result, and drug intervention criteria. However, the primary endpoint is quality of life, not a time-to-event efficacy endpoint as required by the adjudication protocol. | 待处理 |
| Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.Lancet | PMID 38521086无 PMCID | 2024-Apr-06 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Survival, neurocognitive function, and health-related quality of life outcomes after rituximab-methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study.Neuro Oncol | PMID 38037691PMC10995504 | 2024-Apr-05 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19.N Engl J Med | PMID 38598573PMC11156287 | 2024-Apr-04 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial.Signal Transduct Target Ther | PMID 38565886PMC10987514 | 2024-Apr-03 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Hepatic arterial infusion pump chemotherapy combined with systemic chemotherapy for borderline resectable and unresectable colorectal liver metastases: phase II feasibility study.Br J Surg | PMID 38608150无 PMCID | 2024-Apr-03 | 0.95 | The study is a single-arm Phase II feasibility trial, not a randomized Phase III/IIIb or Phase II/III trial. It lacks a randomized control group. The primary endpoint is feasibility (completion of cycles), not a time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, or TTP. The publication type includes 'Clinical Trial, Phase II' and the abstract explicitly states it is a single-arm Phase II study. A subsequent Phase III randomized trial is mentioned as a future direction but is not the subject of this report. | 待处理 |
| Use of 5-ALA fluorescence-guided surgery versus white-light conventional microsurgery for the resection of newly diagnosed glioblastomas (RESECT study): a French multicenter randomized phase III study.J Neurosurg | PMID 37856381无 PMCID | 2024-Apr-01 | 0.90 | The study is a Phase III randomized trial in human oncology with time-to-event endpoints, but the intervention is not a drug-containing therapeutic intervention for oncological efficacy. 5-ALA is a fluorescent agent used to guide surgery, not a therapeutic drug. The primary endpoint is surgical resection rate. Therefore, it does not meet the drug intervention criterion. | 待处理 |
| FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation.Clin Cancer Res | PMID 38010220PMC10984783 | 2024-Apr-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.Int J Gynecol Cancer | PMID 38129136PMC10982633 | 2024-Apr-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Comparison of the Efficacy of HSK3486 and Propofol for Induction of General Anesthesia in Adults: A Multicenter, Randomized, Double-blind, Controlled, Phase 3 Noninferiority Trial.Anesthesiology | PMID 38150544无 PMCID | 2024-Apr-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Quantifying Intrafraction Motion and the Impact of Gating for Magnetic Resonance Imaging-Guided Stereotactic Radiation therapy for Prostate Cancer: Analysis of the Magnetic Resonance Imaging Arm From the MIRAGE Phase 3 Randomized Trial.Int J Radiat Oncol Biol Phys | PMID 38160916无 PMCID | 2024-Apr-01 | 0.85 | The record describes a secondary analysis of a Phase III randomized controlled trial (MIRAGE) for prostate cancer, meeting oncology, human, randomized, and phase criteria. However, the abstract does not report survival, progression, recurrence, death, hazard, time-to-event, or closely related efficacy outcomes; it focuses on technical motion analysis and acute toxicity, not definitive efficacy endpoints required for inclusion. | 待处理 |
| Does Topical Vancomycin Powder Use in Fracture Surgery Change Bacteriology and Antibiotic Susceptibilities? An Analysis of the VANCO Trial.J Orthop Trauma | PMID 38206761无 PMCID | 2024-Apr-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Secondary Analysis of the Rate of Second Primary Lung Cancer From Cancer and Leukemia Group B 140503 (Alliance) Trial of Lobar Versus Sublobar Resection for T1aN0 Non-Small-Cell Lung Cancer.J Clin Oncol | PMID 38215351PMC11003504 | 2024-Apr-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19).J Clin Oncol | PMID 38261983PMC11637124 | 2024-Apr-01 | 0.95 | While all primary eligibility criteria are met (oncology, human, randomized Phase III, time-to-event endpoint, drug intervention, original result), the report is explicitly identified as an interim analysis. The cohort definition requires 'original formal-result reports', and an interim analysis is typically not considered the final formal result. | 待处理 |
| Efficacy, Safety, and Population Pharmacokinetics of MW032 Compared With Denosumab for Solid Tumor-Related Bone Metastases: A Randomized, Double-Blind, Phase 3 Equivalence Trial.JAMA Oncol | PMID 38329745PMC10853867 | 2024-Apr-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial.JAMA Oncol | PMID 38358753PMC10870227 | 2024-Apr-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Fezolinetant treatment of moderate-to-severe vasomotor symptoms due to menopause: effect of intrinsic and extrinsic factors in two phase 3 studies (SKYLIGHT 1 and 2).Menopause | PMID 38517210PMC11896090 | 2024-Apr-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Intravesical Interferon Therapy vs Hyaluronic Acid for Pain Among Female Individuals With Interstitial Cystitis: A Randomized Clinical Trial.JAMA Netw Open | PMID 38587846PMC11002698 | 2024-Apr-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effectiveness of Group Health Education on "Perceived Stress" among High-School Children of Kolar: A Cluster Randomized Controlled Trial.Indian J Public Health | PMID 38953806无 PMCID | 2024-Apr-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| KESTREL and KITE Phase 3 Studies: 100-Week Results With Brolucizumab in Patients With Diabetic Macular Edema.Am J Ophthalmol | PMID 37460036无 PMCID | 2024-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-term efficacy and safety of adjunctive perampanel in patients from the Asia-Pacific region with refractory focal-onset seizures in Study 335 open-label extension.Epilepsia Open | PMID 37867420PMC10984284 | 2024-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study: An analysis with considerations for future studies.J Eur Acad Dermatol Venereol | PMID 37907280无 PMCID | 2024-Apr | 0.99 | 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 | 待处理 |
| Baricitinib treatment rapidly improves the four signs of atopic dermatitis assessed by Eczema Area and Severity Index (EASI) clinical subscores.J Eur Acad Dermatol Venereol | PMID 38041556无 PMCID | 2024-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Rituximab with standard LMB chemotherapy in pediatric high-risk mature B-cell non-Hodgkin lymphoma: A report from the JPLSG B-NHL14 trial.Eur J Haematol | PMID 38112205无 PMCID | 2024-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis.J Am Acad Dermatol | PMID 38122848无 PMCID | 2024-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.Lancet Infect Dis | PMID 38141632无 PMCID | 2024-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Response to Individualized vs. conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial.Fertil Steril | PMID 38147958无 PMCID | 2024-Apr | 0.99 | 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 | 待处理 |